VANCOUVER,Aug.23,/PRNewswire/-CyonTherapeuticsInc.(Cyon)todayannouncedthatithasenteredintoalicenseagreementwithNovartisAG(NYSE:NVS)fortheiranti-PCSK9antibody,LGT-.ThelicensingdealbringswithitworldwiderightsforuseinSIRS(systemicinflammatoryresponsesyndrome)andthepreventionandtreatmentofsepsis.CyonplanstomoveimmediatelyintoaPhaseIIclinicalprogramwiththeantibody;thePhase1alreadysuccessfully







































白癜风初期怎样治疗
皮肤白癜风专家